For an adult patient without renal impairment, which IL‑1 antagonist should be used and what are the recommended dosing and monitoring guidelines?

IL-1 Antagonist Selection and Dosing for Adults Without Renal Impairment

For an adult patient without renal impairment requiring IL-1 blockade, anakinra is the preferred first-line agent due to its short half-life, excellent safety profile, and rapid reversibility, with standard dosing of 100 mg subcutaneously daily. 1

Agent Selection Algorithm

First-Line: Anakinra

• Preferred initial choice when bacterial infection remains on differential diagnosis 1
• Short half-life allows rapid discontinuation if complications arise
• Most extensively studied safety profile across inflammatory conditions 2
• Blocks both IL-1α and IL-1β by antagonizing the IL-1 receptor type 1 2

Alternative Agents

Canakinumab and rilonacept are alternative IL-1 inhibitors used for specific IL-1-mediated autoinflammatory diseases (CAPS, TRAPS, MKD, DIRA) 3, 4. However, the 2024 EULAR/PRES guidelines for Still's disease specifically highlight anakinra's preferential use due to its pharmacokinetic advantages 1.

Dosing Guidelines

Anakinra

• Standard dose: 100 mg subcutaneously once daily
• Continue until clinical inactive disease (CID) is achieved
• Maintain for 3-6 months after achieving CID off glucocorticoids before considering tapering 1

Glucocorticoid Co-Administration Strategy

The dosing approach depends on disease severity:

High severity presentations (high spiking fever, widespread polyarthritis, pain VAS >6-7/10, pericarditis, elevated liver function tests):

• High-dose glucocorticoids indicated initially
• Progressive taper as soon as possible
• Target: CID on low-dose GC at 3 months
• Target: CID off GC at 6 months 1

Milder presentations:

• Low or intermediate dose GC (not mandatory)
• Same tapering timeline if initiated

Monitoring Protocol

Treatment Response Assessment

• 3-month checkpoint: Assess for CID on low-dose glucocorticoids
• 6-month checkpoint: Assess for CID off glucocorticoids
• Failure to meet either target: Consider IL-1/IL-6 inhibitor rotation 1

Safety Monitoring

• Injection site reactions (most common dose-dependent adverse event) 5
• Infection surveillance (particularly if immunosuppression present)
• The safety record for IL-1 blockade is excellent compared to other cytokine-blocking therapies 2

Critical Decision Points

When to Rotate Therapy

If CID off glucocorticoids is not achieved after 6 months despite anakinra, rotate to alternative IL-1 inhibitor (canakinumab, rilonacept) or IL-6 inhibitor while continuing slow GC taper 1.

Difficult-to-Treat (D2T) Criteria

Patients failing to achieve CID off GC after IL-1/IL-6 inhibitor rotation require:

• Multidisciplinary discussion with Still's disease expert
• Consider reference center consultation (e.g., ERN-RITA in Europe)
• Alternative options: JAK inhibitors, immunosuppressants, or hematopoietic stem cell transplantation 1

Common Pitfalls to Avoid

1. Premature biologic tapering: Maintain IL-1 inhibitor for at least 6 months of CID off GC before considering dose reduction 1

2. Inadequate GC tapering: Failure to aggressively taper glucocorticoids leads to prolonged steroid exposure and associated morbidity

3. Delayed treatment escalation: If targets at 3 or 6 months are not met, promptly rotate therapy rather than continuing ineffective treatment 1

4. Overlooking infection: The short half-life of anakinra makes it particularly suitable when infection cannot be excluded, as it can be rapidly discontinued 1